The 30-month stay under the Hatch-Waxman Act delays generic drug approval when brand companies sue over patents. It was meant to balance innovation and access-but today, it often extends market exclusivity by years.
1
Dec
The 30-month stay under the Hatch-Waxman Act delays generic drug approval when brand companies sue over patents. It was meant to balance innovation and access-but today, it often extends market exclusivity by years.
